While this antibody has proven extremely useful for early stage HER2+ breast cancer patients, the majority of late stage (metastatic) patients demonstrate de novo resistance or will develop acquired resistance within 1 to 2 years of trastuzumab treatment [3–5]. This evidence concerns the gene ERBB2 and breast cancer.